2015
Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials
Brener SJ, Mehran R, Lansky AJ, Ayele GM, Stone GW. Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. European Heart Journal Acute Cardiovascular Care 2015, 5: 449-454. PMID: 26722003, DOI: 10.1177/2048872615624848.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeHORIZONS-AMI trialCoronary syndromeAspirin pretreatmentMyocardial infarctionCardiac deathStent thrombosisSegment elevation acute coronary syndromesST-segment elevation myocardial infarctionElevation acute coronary syndromeAcute coronary syndrome patientsLarge randomized clinical trialsAdverse ischemic eventsTarget vessel revascularizationCoronary syndrome patientsIndependent risk factorElevation myocardial infarctionLarge prospective studiesHigh-risk cohortIncidence of deathRandomized clinical trialsMultivariable regression analysisPrior revascularizationVessel revascularizationIschemic events
2012
Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Yu J, Mehran R, Dangas GD, Claessen BE, Baber U, Xu K, Parise H, Fahy M, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone GW. Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2012, 5: 1231-1238. PMID: 23257371, DOI: 10.1016/j.jcin.2012.07.016.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionLow-dose aspirinElevation myocardial infarctionHigh-dose aspirinPrimary PCIHORIZONS-AMI trialPercutaneous coronary interventionMyocardial infarctionMajor bleedingCoronary interventionIschemic target vessel revascularizationMajor adverse cardiovascular eventsCoronary artery bypass surgeryLong-term patient outcomesAdverse ischemic eventsAdverse cardiovascular eventsDose of aspirinTarget vessel revascularizationArtery bypass surgeryHistory of hypertensionPremature coronary diseaseLong-term outcomesIschemic benefitAspirin dose
2010
Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW, Investigators S. Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovascular Interventions 2010, 3: 1220-1228. PMID: 21232715, DOI: 10.1016/j.jcin.2010.07.017.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicAspirinClopidogrelConfidence IntervalsCoronary Artery DiseaseDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsProportional Hazards ModelsRandomized Controlled Trials as TopicRiskRisk Reduction BehaviorSirolimusTiclopidineTime FactorsConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsAdverse cardiac eventsTarget vessel failureCardiac eventsMyocardial infarctionSPIRIT IIProbable stent thrombosisAcademic Research ConsortiumEverolimus-eluting stentsVessel failureSignificant reductionLesion revascularizationPES patientsRevascularization eventsIII trialsClinical outcomesEE patientsStent thrombosisPooled analysisCumulative ratePersistent reductionSPIRIT IIIPatientsStents
2009
Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction
RABBANI LE, IYENGAR S, DANGAS GD, GRINES CL, COX DA, GARCIA E, TCHENG JE, GRIFFIN JJ, GUAGLIUMI G, STUCKEY T, TURCO M, STANT J, FAHY M, LANSKY AJ, MEHRAN R, STONE GW. Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Journal Of Interventional Cardiology 2009, 22: 378-384. PMID: 19496901, DOI: 10.1111/j.1540-8183.2009.00474.x.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinConfidence IntervalsDrug Therapy, CombinationDrug-Eluting StentsFemaleHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsPreoperative CarePyridinesTime FactorsConceptsMajor adverse cardiovascular eventsAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationPrimary stentingThienopyridine administrationLoading doseTH patientsStent implantationMyocardial infarctionClopidogrel loading doseAdverse cardiovascular eventsSuperior clinical outcomesBare-metal stentingAbciximab useCADILLAC trialCardiovascular eventsVessel revascularizationClinical outcomesMetal stentingProcedural characteristicsOperator's discretionPatientsStentingCore labA Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus Restenosis
Liu X, Doi H, Maehara A, Mintz GS, de Ribamar Costa J, Sano K, Weisz G, Dangas GD, Lansky AJ, Kreps EM, Collins M, Fahy M, Stone GW, Moses JW, Leon MB, Mehran R. A Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus Restenosis. JACC Cardiovascular Interventions 2009, 2: 428-434. PMID: 19463466, DOI: 10.1016/j.jcin.2009.01.011.Peer-Reviewed Original ResearchConceptsStent thrombosis groupIntravascular ultrasound findingsMinimum stent areaStent areaThrombosis groupISR groupStent thrombosisUltrasound findingsIntravascular Ultrasound ComparisonProximal stent segmentISR patientsDES thrombosisEdge dissectionStent underexpansionUltrasound comparisonStent fractureThrombosis patientsEarlier drugsStent restenosisThrombosisPatientsStent expansionStent segmentRestenosisLesions
2008
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial
Lansky AJ, Tsuchiya Y, Brener M, Mehran R, Cristea E, Pietras C, Grines CL, Cox DA, Garcia E, Tcheng JE, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Leon MB, Moses J, Stone GW. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheterization And Cardiovascular Interventions 2008, 72: 917-924. PMID: 19016469, DOI: 10.1002/ccd.21714.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinClopidogrelCoronary AngiographyDrug Therapy, CombinationEuropeFemaleHemorrhageHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionMyocardial IschemiaPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentStentsThrombosisTiclopidineTime FactorsTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionPrimary stentingCADILLAC trialRecurrent ischemiaSevere bleedingMyocardial infarctionEfficacy of clopidogrelMore recurrent ischemiaTIMI 0/1 flowSimilar clinical outcomesTiclopidine treatmentAngiographic characteristicsClopidogrel useIndependent predictorsClinical outcomesMultivariable analysisRandomized trialsStent thrombosisStent implantationOperator's discretionClopidogrelStentingPatientsTiclopidineRelative safety
2004
Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction
Kandzari DE, Tcheng JE, Grines CL, Cox DA, Stuckey T, Griffin JJ, Turco M, Garcia E, Carroll JD, Fahy M, Lansky AJ, Mehran R, Stone GW, Investigators C. Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. The American Journal Of Cardiology 2004, 94: 1029-1033. PMID: 15476618, DOI: 10.1016/j.amjcard.2004.06.060.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionAspirin useMyocardial infarctionPrimary percutaneous coronary interventionInfluence of admissionPrimary coronary angioplastyProspective multicenter trialPercutaneous coronary interventionTime of admissionCoronary interventionCoronary angioplastyMulticenter trialInfarctionAdmissionAngioplastyPatientsTrialsOutcome in Elderly Patients Undergoing Primary Coronary Intervention for Acute Myocardial Infarction
Guagliumi G, Stone GW, Cox DA, Stuckey T, Tcheng JE, Turco M, Musumeci G, Griffin JJ, Lansky AJ, Mehran R, Grines CL, Garcia E. Outcome in Elderly Patients Undergoing Primary Coronary Intervention for Acute Myocardial Infarction. Circulation 2004, 110: 1598-1604. PMID: 15353506, DOI: 10.1161/01.cir.0000142862.98817.1f.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdrenergic beta-AntagonistsAdultAge FactorsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinCohort StudiesCombined Modality TherapyCoronary AngiographyCoronary RestenosisFemaleHemorrhageHumansImmunoglobulin Fab FragmentsLife TablesMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsProportional Hazards ModelsPyridinesStentsStrokeTreatment OutcomeConceptsAcute myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsElderly patientsPercutaneous coronary interventionMajor bleedingYears of ageCoronary interventionClinical outcomesStent implantationMyocardial infarctionPlatelet glycoprotein IIb/IIIa inhibitorsDecile of ageMechanical reperfusion strategiesOne-year mortalityPrimary coronary interventionRate of strokeCoronary stent implantationImpact of ageRate of mortalityAbciximab administrationCADILLAC trialReperfusion modalityTarget revascularization
2003
Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent
Mehran R, Aymong ED, Ashby DT, Fischell T, Whitworth H, Siegel R, Thomas W, Wong SC, Narasimaiah R, Lansky AJ, Leon MB. Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent. Circulation 2003, 108: 1078-1083. PMID: 12925457, DOI: 10.1161/01.cir.0000086347.31341.f9.Peer-Reviewed Original ResearchConceptsStent thrombosisIntracoronary stentingNon-Q-wave myocardial infarctionMajor adverse cardiac eventsNative coronary artery lesionsAdverse cardiac eventsBlunt chest traumaPrimary end pointCoronary artery lesionsNative coronary arteriesDevastating clinical consequencesBalloon-expandable stentsAspirin monotherapyAnticoagulation therapyArtery lesionsCardiac eventsChest traumaInfrequent complicationSelect patientsProcedural successRestenotic lesionsCoronary arteryOptimal stentingMyocardial infarctionClinical consequences
2001
Stent Thrombosis in the Modern Era
Cutlip D, Baim D, Ho K, Popma J, Lansky A, Cohen D, Carrozza J, Chauhan M, Rodriguez O, Kuntz R. Stent Thrombosis in the Modern Era. Circulation 2001, 103: 1967-1971. PMID: 11306525, DOI: 10.1161/01.cir.103.15.1967.Peer-Reviewed Original ResearchMeSH KeywordsAspirinBlood Vessel Prosthesis ImplantationCausalityCoronary DiseaseCoronary ThrombosisEndpoint DeterminationFemaleGraft Occlusion, VascularHumansIncidenceLogistic ModelsMaleMiddle AgedMulticenter Studies as TopicMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicSurvival RateTiclopidineTreatment OutcomeConceptsTotal stent lengthStent thrombosisAntiplatelet therapyStent lengthClinical consequencesFinal minimal lumen diameterLumen diameterNative coronary artery lesionsAngiographic stent thrombosisClinical stent thrombosisHigh-pressure deploymentRoutine antiplatelet therapyCoronary artery lesionsIncidence of deathMinimal lumen diameterProcedure-related variablesSecond-generation stentsCoronary stent trialsSerious clinical consequencesFinal lumen diameterNonrandomized registryAntithrombotic regimensArtery lesionsPersistent dissectionMyocardial infarctionCombination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting
Dangas G, Mehran R, Abizaid A, Curry B, Lansky A, Kent K, Pichard A, Satler L, Paliou M, Stone G, Leon M. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. The American Journal Of Cardiology 2001, 87: 470-472. PMID: 11179539, DOI: 10.1016/s0002-9149(00)01408-9.Peer-Reviewed Original Research
1998
Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty
Popma J, Weitz J, Bittl J, Ohman E, Kuntz R, Lansky A, King S. Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty. CHEST Journal 1998, 114: 728s-741s. PMID: 9822074, DOI: 10.1378/chest.114.5_supplement.728s.Peer-Reviewed Original Research